S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
NASDAQ:GPCR

Structure Therapeutics (GPCR) Stock Price, News & Analysis

$43.27
-0.33 (-0.76%)
(As of 02/28/2024 ET)
Today's Range
$42.79
$44.94
50-Day Range
$33.00
$49.14
52-Week Range
$21.12
$75.02
Volume
545,452 shs
Average Volume
480,800 shs
Market Capitalization
$2.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$81.14

Structure Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
106.1% Upside
$89.17 Price Target
Short Interest
Bearish
8.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.00mentions of Structure Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.86) to ($0.98) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.83 out of 5 stars

Medical Sector

720th out of 958 stocks

Pharmaceutical Preparations Industry

314th out of 417 stocks


GPCR stock logo

About Structure Therapeutics Stock (NASDAQ:GPCR)

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

GPCR Stock Price History

GPCR Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
GPCR Mar 2024 60.000 call
Baron Opportunity Fund Q4 2023 Shareholder Letter
Here’s Why Structure Therapeutics (GPCR) Fell in Q4
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc ADR
11 Best Young Stocks to Buy and Hold For 20 Years
See More Headlines
Receive GPCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GPCR
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$81.14
High Stock Price Target
$97.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+87.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-51,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$2.01 billion
Optionable
Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Raymond C. Stevens Ph.D. (Age 60)
    CEO & Director
    Comp: $747.33k
  • Dr. Yingli Ma Ph.D. (Age 50)
    Chief Technology Officer
    Comp: $497.58k
  • Dr. Mark A. Bach M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $628.37k
  • Mr. Jun S. Yoon (Age 46)
    Co- Founder, CFO & Secretary
  • Dr. Xichen Lin Ph.D. (Age 50)
    Chief Scientific Officer
  • Mr. Tony Peng
    Senior Vice President of Legal
  • Mr. Bob Gatmaitan
    Senior Vice President of People
  • Dr. Hui Lei Ph.D.
    Senior Vice President of Chemistry
  • Dr. Fang Zhang Ph.D.
    Executive VP & Head of Biology
  • Ms. Lani Ibarra
    Senior Vice President of Clinical Development Operations














GPCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Structure Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GPCR shares.
View GPCR analyst ratings
or view top-rated stocks.

What is Structure Therapeutics' stock price target for 2024?

4 brokerages have issued 1 year target prices for Structure Therapeutics' stock. Their GPCR share price targets range from $79.00 to $97.00. On average, they anticipate the company's share price to reach $89.17 in the next twelve months. This suggests a possible upside of 106.1% from the stock's current price.
View analysts price targets for GPCR
or view top-rated stocks among Wall Street analysts.

How have GPCR shares performed in 2024?

Structure Therapeutics' stock was trading at $40.76 at the beginning of 2024. Since then, GPCR stock has increased by 6.2% and is now trading at $43.27.
View the best growth stocks for 2024 here
.

Are investors shorting Structure Therapeutics?

Structure Therapeutics saw a increase in short interest in February. As of February 15th, there was short interest totaling 2,500,000 shares, an increase of 7.3% from the January 31st total of 2,330,000 shares. Based on an average trading volume of 836,400 shares, the short-interest ratio is currently 3.0 days. Currently, 8.7% of the shares of the stock are short sold.
View Structure Therapeutics' Short Interest
.

When is Structure Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our GPCR earnings forecast
.

What ETFs hold Structure Therapeutics' stock?

ETFs with the largest weight of Structure Therapeutics (NASDAQ:GPCR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Fidelity Disruptive Medicine ETF (FMED).

When did Structure Therapeutics IPO?

(GPCR) raised $150 million in an initial public offering (IPO) on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share.

Who are Structure Therapeutics' major shareholders?

Structure Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (5.03%), Federated Hermes Inc. (4.89%), Price T Rowe Associates Inc. MD (3.62%), Price T Rowe Associates Inc. MD (3.62%), Capital Research Global Investors (2.10%) and Capital International Investors (1.83%).

How do I buy shares of Structure Therapeutics?

Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GPCR) was last updated on 2/29/2024 by MarketBeat.com Staff